Provided by Tiger Trade Technology Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

358.77
-7.1700-1.96%
Pre-market: 351.52-7.2500-2.02%04:00 EDT
Volume:351.45K
Turnover:127.09M
Market Cap:40.90B
PE:64.19
High:371.09
Open:367.94
Low:358.32
Close:365.94
52wk High:385.22
52wk Low:253.95
Shares:114.00M
Float Shares:80.95M
Volume Ratio:0.92
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.59
EPS(LYR):2.47
ROE:14.66%
ROA:7.46%
PB:7.90
PE(LYR):145.25

Loading ...

Lithium Carbonate Spot Prices Surge Significantly; BEIGENE Reports 178-Fold Jump in Q1 Net Profit

Stock News
·
May 07

Stock Track | BeOne Medicines Soars 5.19% Intraday on Strong Q1 2026 Earnings and Positive Guidance

Stock Track
·
May 06

BEIGENE Reports Q1 2026 Net Profit of 1.608 Billion Yuan

Stock News
·
May 06

GUIDANCE: (ONC) BeOne Medicines Expects 2026 Revenue Range $6.3B - $6.5B, vs. FactSet Est of $6.4B

MT Newswires Live
·
May 06

Press Release: BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates

Dow Jones
·
May 06

Is It Too Late To Consider BeOne Medicines (ONC) After Its 23% One Year Gain?

Simply Wall St.
·
May 06

BeOne Medicines AG expected to post earnings of 87 cents a share - Earnings Preview

Reuters
·
May 04

BeOne Medicines Receives US FDA Priority Review for Tevimbra Combination Therapy

MT Newswires Live
·
Apr 29

Earning Preview: BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS this quarter’s revenue is expected to increase by 17.70%, and institutional views are bullish

Earnings Agent
·
Apr 29

BEIGENE Secures Global Exclusive Rights to Develop Trispecific Therapy Through Huahui Anjian Partnership

Stock News
·
Apr 27

Press Release: BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6

Dow Jones
·
Apr 22

Beigene Reports Profit Turnaround with 2025 Net Income of 1.461 Billion Yuan

Stock News
·
Apr 14

Analysts Conflicted on These Healthcare Names: Johnson & Johnson (JNJ), BeOne Medicines (ONC) and Helus Pharma (HELP)

TIPRANKS
·
Apr 13

BeOne Medicines (ONC) Receives a Buy from Truist Financial

TIPRANKS
·
Apr 10

OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease

prnewswire
·
Apr 09

RBC Capital Keeps Their Buy Rating on BeOne Medicines (ONC)

TIPRANKS
·
Apr 09

BEIGENE Grants 17,700 Restricted Stock Units in Form of ADSs

Stock News
·
Apr 08

Truist Financial Remains a Buy on BeOne Medicines (ONC)

TIPRANKS
·
Apr 06